A previous study by our group demonstrated that the expression levels of Notch 1 and Jagged 1 in bladder cancer cells was significantly lower compared with those in normal bladder mucosa, while the expression levels of Notch 1 and Jagged 1 in invasive bladder cancer were higher compared with those in superficial bladder cancer. The present study investigated the effect of the Notch signaling pathway on the drug resistance and invasiveness of bladder cancer cells. It was demonstrated that complete inhibition of the Notch signaling pathway induced significant morphological changes and inhibited cell proliferation and migration (P<0.05). Reverse transcription quantitative polymerase chain reaction and western blot analyses revealed that the mRNA and protein expression levels of E-cadherin were upregulated (P<0.05) and the mRNA and protein expression levels of N-cadherin, vimentin and α-smooth muscle actin were downregulated (P<0.05). The present study concluded that complete inhibition of the Notch signaling pathway inhibited cell proliferation and invasion, and reduced drug resistance in bladder cancer cells, a phenomenon which may be associated with the inhibition of the epithelial-mesenchymal transition.
Introduction
Bladder cancer is the most ubiquitous malignant urinary tumor, and is susceptible to recurrence, invasion and metastasis. However, there are only a few studies describing the mechanisms of invasion and metastasis (1) . Investigations into the epithelial-mesenchymal transition (EMT) have provided an increased understanding of the invasion and metastasis of cancer (2) (3) (4) . The EMT is a biological process, which occurs under specific conditions and interacts with the basement membrane, in which epithelial cells gradually transform into cells with mesenchymal properties. Cancer cells undergoing the EMT process are depolarized and transformed, which enables them to invade and metastasize, accompanied by the inhibition of apoptosis and degradation of the extracellular matrix (5) (6) (7) . In a previous study by our group, it was demonstrated that the Notch signaling pathway had an anti-tumorigenic function in superficial bladder cancer (8) . The expression levels of Notch 1 and Jagged 1 in bladder cancer were significantly lower compared with those in normal bladder mucosa, while the expression levels of Notch 1 and Jagged 1 in invasive bladder cancer were higher compared with those in superficial bladder cancer (9) . Based on these previous studies, the present study hypothesized that the Notch signaling pathway is important in the invasion and metastasis of bladder cancer. In the preset study, the Notch signaling pathway was completely inhibited in the bladder cancer cell lines T24, 5637 and J82 using a γ-secretase inhibitor (GSI). The cellular morphology, drug resistance and invasiveness were subsequently analyzed. The effect of the Notch signaling pathway on the invasion and drug resistance of bladder cancer was assessed by measuring the alterations in the expression levels of the molecular biomarkers associated with EMT, with the aim of determining whether Notch signaling modified urinary tumor invasion and drug resistance by affecting the EMT. 
Materials and methods

Cell
Reverse transcription quantitative polymerase chain reaction (RT-qPCR).
Total RNA (1 µg) was used for RT using a Reverse Transcription system (PrimeScript™ RT Reagent kit; Takara Bio, Inc., Shiga, Japan), according to manufacturer's instructions. RT-qPCR was performed using SYBR ® Premix Ex TaqTM II (TliRNase H Plus; Takara Bio, Inc.) on the ABI PRISM ® 7500 real-time PCR system (Applied Biosystems, Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA), with β-actin as an internal control. Thermocycling was performed in a final volume of 20 µl consisting of 40 cycles at 95˚C for 5 sec then 55˚C for 30 sec, following an initial denaturation step at 95˚C for 10 sec. The sequences of the PCR primers of E-cadherin, N-cadherin, vimentin and smooth muscle actin are listed in Table I . The results were analyzed using the 2 -∆∆Ct method. ΔCt = average gene Ct-Δaverage of β-actin Ct. ΔΔCt was calculated as follows: ΔΔCt = ΔCt of sample group-ΔΔCt of control group.
Western blot analysis. The protein concentrations were quantified using a Micro Bicinchoninic Acid Protein Assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA). Identical quantities of total protein from each sample (30 µg) were loaded and separated by 12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. The membranes were incubated with the following primary antibodies at 4˚C overnight: Anti-N-cadherin (1:800; cat. no. ab18203; Abcam, Cambridge, MA, USA), anti-vimentin (1:500; cat. no. 3877; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-α-smooth muscle actin (1:1,000; cat. no. P62736; Abgent, Inc., San Diego, CA, USA), anti-E-cadherin (1:800; cat. no. 5296; Cell Signaling Technology, Inc.), and anti-β-actin (1:1,500; cat. no. ab6276; Abcam). The membranes were then incubated with horseradish peroxidase-conjugated AffiniPure goat anti-rabbit lgG(H+L) secondary antibody (1:10,000; cat. no. ZF-0316-1; ZSGB-BIO, Beijing, China) or horseradish peroxidase-conjugated AffiniPure goat anti-mouse lgG(H+L) secondary antibody (1:10,000; cat. no. ZF-0315-1; ZSGB-BIO) at room temperature for 2 h. The signals were detected using an enhanced chemiluminescence system (cat. no. 32109; Thermo Fisher Scientific) and the films (cat. no. 6535876; Eastman Kodak Company, Rochester, NY, USA) were scanned and analyzed by AlphaEaseFC version 1.1 software (Alpha Innotech, San Leandro, CA, USA).
MTT assay. Cells in the logarithmic growth phase were subcultured in 96-well plates at a cell density of 5,000 cells/well. In each experiment, five wells corresponded to each control group: Mitoxantrone-treated, zero-adjustment wells and control wells. The mitoxantrone wells contained 1, 4, 16, 64 and 256 ng/ml of drug (Sigma-Aldrich, St. Louis, MO, USA). Transwell assay. Transwell plates were coated with 40 µl 50 mg/l Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Cells (300 µl) in the logarithmic growth phase were added to the Transwell plates at a final cell density of 1x10 5 cells/ml. Culture media, supplemented with 20% FBS (800 µl), was added to each well. The plate was incubated at 37˚C and 5% CO 2 for 24 h. The supernatants were subsequently removed from the Transwells, followed by rinsing, fixation with 2 ml 3.7% paraformaldehyde and staining with 2 ml 0.05% crystal violet (Beijing Solarbio Science & Technology). The inner cells were removed using a cotton swab and the number of cells, which were below the microporous membrane, were counted using a microscope (XL-71; Olympus Corporation, Tokyo, Japan). The average cell number from 10 randomly selected fields (magnification, x200) was calculated.
Statistical analysis.
Values are expressed as the mean ± standard error and analyzed using SPSS 12.0 (SPSS, Inc., Chicago, IL, USA). Western blot images were semi-quantitatively analyzed using ImageJ version 2.1 software (National Institutes of Health, Bethesda, MD, USA). The means of two samples were analyzed using the independent sample t-test. P<0.05 was considered to indicate a statistically significant difference between values.
Results
Complete inhibition of the Notch signaling pathway inhibits cell proliferation and induces morphological changes. In order to determine whether the GSI caused morphological changes in bladder cancer cells, T24, 5637 and J82 cells were examined microscopically to assess cell growth and morphological changes following treatment with GSI for 24 h (Fig. 1) . Treatment with GSI significantly reduced the cell density. Intercellular junction formation was also reduced, with the majority of cells exhibiting a shrunken appearance and underwent apoptosis.
Inhibition of the Notch signaling pathway inhibits the EMT.
Following treatment with the GSI to inhibit the Notch signaling pathway, the mRNA expression levels of mesenchymal biomarkers, including N-cadherin, vimentin and α-smooth muscle actin, were downregulated compared with those in the control group and there was a significant upregulation of the mRNA expression of E-cadherin ( Fig. 2; P<0.05) .
Western blot analysis demonstrated that the protein expression levels of N-cadherin, vimentin and α-smooth muscle actin were significantly downregulated following treatment with GSI compared with those in the control group, whereas the protein expression of of E-cadherin was upregulated (Fig. 3) . This observed downregulation of mesenchymal biomarkers and upregulation of epithelial biomarkers indicated that inhibition of Notch signaling inhibited the EMT.
Inhibition of the Notch signaling pathway reduces the drug resistance and invasiveness of bladder cancer cells.
Following treatment with the GSI (5 µM) for 48 h, the T24, 5637 and J82 bladder cancer cells were cultured with different concentrations of the bladder cancer therapeutic mitoxantrone and the cell viability was detected using an MTT assay. The results revealed that the GSI-treated cells exhibited an increased sensitivity to mitoxantrone-induced cytotoxicity compared with that of the control (untreated) cells (Fig. 4; P<0.05) .
Similarly, a Transwell assay demonstrated that the GSI-treated cells were more sensitive to mitoxantrone compared with the untreated cells, as indicated by decreased invasiveness. Treatment with GSI reduced the number of cells which passed through the Transwell membrane, which indicated a deficit in the invasive capacity of those cells which lacked Notch signaling (Fig. 5) . Therefore, the present study demonstrated that inhibiting the Notch signaling pathway inhibited the invasion of bladder cancer cells.
Discussion
Studies have demonstrated that the morbidity of bladder cancer has been increasing in China. Bladder cancer is the most common malignancy of the urinary system, 90% of which 
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are transitional cell carcinoma of the urinary system (5). The proliferation and metastasis of bladder cancer cells involves various transient changes, which involve sequential regulation of a number of different genes and signaling pathways (5, 10, 11) . The Notch signaling pathway and the EMT have been demonstrated to be involved in the proliferation and metastasis of the majority human cancer types (12) (13) (14) (15) . However, the role of Notch signaling and the EMT in bladder cancer cells remains to be elucidated.
The Notch signaling pathway, a conserved signaling pathway, controls cell proliferation, survival, apoptosis, differentiation and the development and function of various organs (16, 17) . It has been previously reported that the activation of the Notch signaling pathway predominantly depends upon the activity of GSI (14) . GSI, as an effective inhibitor of all Notch receptors, has been used clinically to treat several types of carcinoma (18, 19) . The present study analyzed the effect of the GSI on the T24, 5637 and J82 bladder cancer cells. A previous study has indicated that Notch 4 activates mouse mammary tumor virus and causes mammary tumors in mice (20) . Notch 1 and Notch 2 cooperate with the EIA to transform epithelial cells in common rodent models (21, 22) . Previous studies have demonstrated that Notch facilitates cell cycle progression and inhibits cell apoptosis (23). Shi et al (8) revealed that the expression of Notch 1 is decreased in non-invasive bladder cancer, while it is highly expressed in invasive bladder cancer. The present study demonstrated a significant inhibition of cell proliferation upon inhibition of the Notch signaling pathway, suggesting that the Notch signaling pathway may trigger carcinogenesis in bladder cancer, particularly those associated with a high expression of Notch 1.
Accumulating evidence has indicated that there is a correlation between the EMT and metastasis, since the EMT can equip cancer cells with an increased migratory ability (24) . Grego-Bessa et al (25) demonstrated that inducing the EMT caused a downregulation of expression levels of epithelial markers, including E-cadherin, α-catenin and β-catenin, and an upregulation of mesenchymal biomarkers, including N-cadherin, vimentin, fibronectin, matrix metalloproteinase and α-smooth muscle actin. Following complete inhibition of the Notch signaling pathway, T24, 5637 and J82 bladder cancer cells exhibited increased expression of E-cadherin and downregulation of the expression levels of N-cadherin, vimentin and α-smooth muscle actin, as confirmed by RT-qPCR and western blot analysis. In addition, the invasiveness of bladder cancer cells following inhibition of the Notch signaling pathway was significantly reduced. Consequently, these data suggested that inhibiting the Notch signaling pathway inhibited the EMT in bladder cancer cells, thereby reducing cell invasiveness. A previous study also demonstrated that the Slug molecule was one of the vital components in the process of EMT via the Notch signaling pathway (25) . Upregulation of Slug activated the promoter of E-cadherin, resulting in EMT (26, 27) . However, whether the EMT is dependent upon the expression of Slug in bladder cancer remains to be elucidated.
It has been reported that the EMT correlates with drug resistance in cancer, including drug resistance to paclitaxel, vinblastine, oxaliplatin, gemcitabine and epidermal growth factor receptor-targeted agents (28). Shah et al (29) demonstrated that gemcitabine-resistant pancreatic carcinoma cells exhibited the EMT phenotype, alongside downregulation of epithelial markers and upregulation of mesenchymal markers. In addition, activation of the Notch signaling pathway was shown to partially reverse the EMT phenotype (29, 30) . These data suggested that the activation of Notch signaling may trigger the EMT in cancer cells and, therefore, cause drug resistance. The present study revealed that the inhibition of the Notch signaling pathway in bladder cancer cells caused a higher sensitivity to the anti-cancer drug mitoxantrone as compared with that of the control group. The results indicated that regulation of the EMT by the Notch signaling pathway may be associated with drug resistance in bladder cancer, and that Notch inhibition may be utilized to counteract drug resistance.
In conclusion, treatment with the GSI demonstrated that inhibiting the Notch signaling pathway inhibited the EMT of bladder cancer cells. Inhibiting the Notch signaling pathway triggered reversion of EMT-associated biomarker levels and reduced the invasiveness and drug resistance of bladder cancer cells. These data provided further evidence that there is a clear association between the Notch signaling pathway and the EMT. In further studies it is be necessary to identify the key molecule that regulates the EMT through the Notch signaling pathway, so that the precise signaling regulation network for EMT and the Notch signaling pathway can be determined. Finally, it is necessary to investigate novel molecular mechanisms underlying the genesis, metastasis and drug-resistance of bladder cancer in order to develop novel treatment strategies.
